GeneOne Life Science announced on the 23rd that it has received a patent registration in South Korea for the "vaccine composition for the prevention of severe acute respiratory syndrome coronavirus 2 infection."
The company explained that this patent can be widely applied in the field of COVID-19 prevention by adding proteins such as ORF3a protein in addition to the spike protein as antigens for the COVID-19 vaccine, resulting in significant antibody immune response and T-cell immune response effects. It also stated that it aimed to promote rapid and efficient vaccine production by employing a bicistronic strategy that loads two antigens into a single plasmid.
Park Young-geun, CEO of GeneOne Life Science, said, "The technology related to the COVID-19 DNA vaccine (GLS-5310) developed by our company has been recognized for novelty and progressiveness domestically and registered as a patent," adding, "We believe this is the result of demonstrating the capabilities of our nucleic acid-based vaccine development platform for responding to emerging infectious diseases."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
